D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Time From Treatment to Subsequent Diagnosis of Brain Metastases in Stage III Non–Small-Cell Lung Cancer: A Retrospective Review by the Southwest Oncology Group
Laurie E. Gaspar,Kari Chansky,Kathy S. Albain,Eric Vallières,Valerie W. Rusch,John Crowley,Robert B. Livingston,David R. Gandara +7 more
TL;DR: Nonsquamous histology and young patient age were the only significant predictors for increased risk of early relapse with brain metastases in patients undergoing combined-modality therapy for stage III non-small-cell lung cancer.
Journal ArticleDOI
Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Luis Paz-Ares,Jean-Yves Douillard,Piotr Koralewski,Christian Manegold,Egbert F. Smit,Jose Reyes,Gee-Chen Chang,William J. John,Patrick Peterson,Coleman K. Obasaju,Michael Lahn,David R. Gandara +11 more
TL;DR: Adding aprinocarsen to gemcitabine and cisplatin regimen did not enhance survival and other efficacy measures in patients with advanced NSCLC.
Journal ArticleDOI
Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial
David R. Gandara,Everett E. Vokes,Mark R. Green,P. Bonomi,Russell F. DeVore,Robert L. Comis,David Carbone,Daniel D. Karp,Chandra P. Belani +8 more
TL;DR: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC and indicates this novel taxane was relatively well tolerated in this previously treated population.
Journal ArticleDOI
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara,Peter S. Hammerman,Martin L. Sos,Martin L. Sos,Primo N. Lara,Fred R. Hirsch +5 more
TL;DR: The current status of SCC therapeutics, recent advances in the understanding of S CC biology and prognostic gene signatures, and the development of innovative new clinical trials are described, all of which offer new hope for patients with advanced SCC.
Journal ArticleDOI
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
Jonathan W. Riess,David R. Gandara,Garrett M. Frampton,Russell Madison,Nir Peled,Jose A. Bufill,Grace K. Dy,Sai-Hong Ignatius Ou,Philip J. Stephens,John Douglas Mcpherson,Primo N. Lara,Rebekah A. Burich,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Philip C. Mack,Alexa B. Schrock +16 more
TL;DR: Comprehensive sequencing revealed increased proportion and wide variety of EGFRex20ins, representing a population of patients significant enough for focused efforts on effective interventions, a higher frequency than previously reported in smaller single‐institution studies.